174 related articles for article (PubMed ID: 19164422)
1. Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials.
Levy WC; Mozaffarian D; Linker DT; Kenyon KW; Cleland JG; Komajda M; Remme WJ; Torp-Pedersen C; Metra M; Poole-Wilson PA;
Eur J Heart Fail; 2009 Mar; 11(3):256-63. PubMed ID: 19164422
[TBL] [Abstract][Full Text] [Related]
2. [A randomized comparison of carvedilol and metoprolol in patients with chronic heart failure. The Carvedilol Or Metoprolol European Trial (COMET) ].
Torp-Pedersen CT;
Ugeskr Laeger; 2004 Aug; 166(32):2671-4. PubMed ID: 15347171
[No Abstract] [Full Text] [Related]
3. Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET.
Cleland JG
Curr Heart Fail Rep; 2004 Jul; 1(2):82-8. PubMed ID: 16036030
[TBL] [Abstract][Full Text] [Related]
4. The COMET trial.
Bristow MR; Adams KF; Bauman JL; Feldman AM; Giles TD; Goldstein S; Mann DL; Talbert RL
Congest Heart Fail; 2005; 11(1):39-47. PubMed ID: 15722669
[No Abstract] [Full Text] [Related]
5. [The COMET study compares effect of two different beta-blockers in chronic heart failure. Carvedilol better than metoprolol].
Swedberg K
Lakartidningen; 2003 Sep; 100(37):2852-4. PubMed ID: 14558169
[No Abstract] [Full Text] [Related]
6. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
Poole-Wilson PA
Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
[TBL] [Abstract][Full Text] [Related]
7. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
8. [A fairer comparison between carvedilol and metoprolol is still to be done].
Johnsson G; Aberg J
Lakartidningen; 2003 Oct; 100(44):3543-4, 3544-5. PubMed ID: 14651018
[No Abstract] [Full Text] [Related]
9. Has COMET solved the controversy as to whether carvedilol is better than metoprolol in heart failure?
Doggrell SA
Expert Opin Pharmacother; 2004 Jan; 5(1):205-8. PubMed ID: 14680448
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial.
Bauman JL; Talbert RL
J Cardiovasc Pharmacol Ther; 2004 Jun; 9(2):117-28. PubMed ID: 15309248
[TBL] [Abstract][Full Text] [Related]
11. How should COMET influence heart failure practice?
Adams KF
Curr Heart Fail Rep; 2004 Jul; 1(2):67-71. PubMed ID: 16036027
[TBL] [Abstract][Full Text] [Related]
12. A comment on COMET: how to interpret a positive trial?
Massie BM
J Card Fail; 2003 Dec; 9(6):425-8. PubMed ID: 14966781
[No Abstract] [Full Text] [Related]
13. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate.
Delea TE; Stanford R; Hagiwara M; Edelsberg JS; Oster G
Int J Cardiol; 2005 Mar; 99(1):117-24. PubMed ID: 15721509
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
[TBL] [Abstract][Full Text] [Related]
15. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
Poole-Wilson PA; Swedberg K; Cleland JG; Di Lenarda A; Hanrath P; Komajda M; Lubsen J; Lutiger B; Metra M; Remme WJ; Torp-Pedersen C; Scherhag A; Skene A;
Lancet; 2003 Jul; 362(9377):7-13. PubMed ID: 12853193
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial.
Kveiborg B; Major-Petersen A; Christiansen B; Torp-Pedersen C
Vasc Health Risk Manag; 2007; 3(1):31-7. PubMed ID: 17583173
[TBL] [Abstract][Full Text] [Related]
17. Carvedilol and metoprolol European trial: do the results merit challenge?
Smith KM
Am J Health Syst Pharm; 2004 Jun; 61(12):1289-93. PubMed ID: 15259762
[No Abstract] [Full Text] [Related]
18. Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
Packer M
J Card Fail; 2003 Dec; 9(6):429-43. PubMed ID: 14966782
[TBL] [Abstract][Full Text] [Related]
19. Long-term oral carvedilol in chronic heart failure.
Di Lenarda A; Sabbadini G; Moretti M; Sinagra G
Expert Opin Pharmacother; 2004 Jun; 5(6):1359-72. PubMed ID: 15163280
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term beta-blocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy.
Piccirillo G; Quaglione R; Nocco M; Naso C; Moisè A; Lionetti M; Di Carlo S; Marigliano V
Am J Cardiol; 2002 Nov; 90(10):1113-7. PubMed ID: 12423713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
